Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Burns

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Bioorganic & Medicinal Chemistry Letters|July 3, 2007
Indanylacetic acids as PPAR-delta activator insulin sensitizersPhilip Wickens, Chengzhi Zhang, Xin Ma, et al.
PLOS Digital Health|December 30, 2025
Correction: Eliminating the AI digital divide by building local capacityFreya Gulamali, Jee Young Kim, Kartik Pejavara, et al.
PLOS Digital Health|October 23, 2025
Eliminating the AI digital divide by building local capacityFreya Gulamali, Jee Young Kim, Kartik Pejavara, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Bioorganic & Medicinal Chemistry Letters|July 3, 2007
Indanylacetic acids as PPAR-delta activator insulin sensitizersPhilip Wickens, Chengzhi Zhang, Xin Ma, et al.
PLOS Digital Health|December 30, 2025
Correction: Eliminating the AI digital divide by building local capacityFreya Gulamali, Jee Young Kim, Kartik Pejavara, et al.
PLOS Digital Health|October 23, 2025
Eliminating the AI digital divide by building local capacityFreya Gulamali, Jee Young Kim, Kartik Pejavara, et al.
Pageof 5